Graft-vs-Host Disease
Information
- Disease name
- Graft-vs-Host Disease
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02409134 | Completed | Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking Vorinostat | April 2015 | April 2018 | |
| NCT00189761 | Completed | Phase 2 | A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients | ||
| NCT01318330 | Completed | Phase 1 | Safety Study of Homeo-GH (Bone Marrow Derived Clonal Mesenchymal Stem Cell) to Treat Acute/Chronic Graft Versus Host Disease (GVHD) | November 2010 | June 2012 |
| NCT01512498 | Completed | Vulvovaginal Graft Versus Host Disease (VV-GVHD) in Women Who Underwent Transplantation Before and After Menarche | December 2012 | December 2018 | |
| NCT00031148 | Completed | Phase 1/Phase 2 | Keratinocyte Growth Factor to Prevent Acute GVHD | September 2001 | August 2003 |
| NCT00189748 | Completed | Phase 2 | A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension- | August 2004 | |
| NCT01940796 | Terminated | Phase 1 | Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD) | October 2013 | December 2016 |
| NCT01994824 | Terminated | Phase 2 | Preemptive Therapy of GVHD | January 2014 | September 27, 2021 |
| NCT00548717 | Terminated | Phase 2 | Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation | October 2007 | September 2013 |
| NCT00032279 | Unknown status | Phase 2 | Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease | March 2002 |